Articles

P1.17 DNA hydroxymethylation in chronic lymphocytic leukemia: TET and IDH mRNA expression, prognostic significance and influence of microenvironment

BJH - volume 6, issue Abstract Book BHS, january 2015

M. Van Damme , E. Crompot , N. Meuleman MD, PhD, P. Mineur MD, D. Bron MD, PhD, L. Lagneaux , B. Stamatopoulos

Read more

P2.08 Short delay of occurrence of myelodysplasia after Peptide Receptor Radionuclide Therapy (PRRT) in neuroendocrine tumors (NETs)

BJH - volume 6, issue Abstract Book BHS, january 2015

G. Claes MD, J. Nguyen , N. Charette , G. Machiels , M. Vercruyssen MD, S. Wittnebel MD, PhD, N. Meuleman MD, PhD, D. Bron MD, PhD

Read more

Update on the initial therapy of multiple myeloma

BJH - volume 5, issue 4, december 2014

M.C. Vekemans MD, K. Beel MD, PhD, J. Caers MD, PhD, N. Meuleman MD, PhD, G. Bries MD, PhD, V. Delrieu MD, H. Demuynck MD, B. De Prijck MD, H. De Samblanx MD, A. Deweweire MD, A. Kentos MD, PhD, P. Mineur MD, F. Offner MD, PhD, I. Vande Broek MD, PhD, A. Vande Velde MD, J. Van Droogenbroeck MD, KL. Wu MD, PhD, C. Doyen MD, R. Schots MD, PhD, M. Delforge MD, PhD

Summary

With the introduction of immunomodulatory drugs and proteasome inhibitors, major improvements have been achieved in the treatment and prognosis of multiple myeloma. Different treatment combinations are now in use and innovative therapies are being developed. This rapidly changing therapeutic landscape calls for an update on the Belgian myeloma guidelines, published in 2010.1 Based on an extensive review of the recent literature, the myeloma study group of the Belgian Hematology Society has revised the consensus recommendations on myeloma care, to be used by haematologists as a reference for daily practice. When applicable, comments with regards to the Belgian reimbursement modalities are included. The full text with appendices can be downloaded from the Belgian Hematology Society website (www.bhs.be) and from the Belgium Journal of Hematology website (www.ariez.com).

(BELG J HEMATOL 2014;5(4):125–36)

Read more

P2.05 Global HDAC enzymatic activity is a strong marker of poor prognosis in Chronic Lymphocytic Leukemia

BJH - volume 5, issue Abstract Book BHS, january 2014

M. Van Damme , E. Crompot , N. Meuleman MD, PhD, P. Mineur MD, B. Dessars MD, PhD, H. El Housni , D. Bron MD, PhD, L. Lagneaux , B. Stamatopoulos

Read more

P2.01 Downregulation of cellular microRNA-150 is a new prognostic factor associated with a poor prognosis in Chronic Lymphocytic Leukemia patients

BJH - volume 5, issue Abstract Book BHS, january 2014

B. Stamatopoulos , N. Meuleman MD, PhD, E. Crompot , M. Van Damme , B. Dessars MD, PhD, H. El Housni , P. Mineur MD, D. Bron MD, PhD, L. Lagneaux

Read more

P2.04 Immune impairments of the multiple myeloma bone-marrow mesenchymal stromal cells

BJH - volume 5, issue Abstract Book BHS, january 2014

T. André , M. Najar , B. Stamatopoulos , K. Pieters , O. Pradier MD, PhD, D. Bron MD, PhD, N. Meuleman MD, PhD, L. Lagneaux

Read more

P2.21 Post-Transplant Lymphoproliferative Disorder following solid organ transplantation

BJH - volume 5, issue Abstract Book BHS, january 2014

J. Dallemagne , M-C. Ngirabacu MD, PhD, V. De Wilde MD, PhD, B. Bailly MD, F. Benghiat , M. Maerevoet MD, M.F. Dehou MD, N. Meuleman MD, PhD, D. Bron MD, PhD

Read more